The new St. Jude Medical Invisible Trial System was designed to help patients with chronic pain to better assess the effect of spinal cord stimulation therapy prior to permanent implant.
St. Jude Medical awaits approval for spinal cord stimulation therapy from the European regulatory. Physicians can program the stimulator, analyze results and communicate with a paired iPad mini.
The new St. Jude Medical system relies on Bluetooth communication, providing a secure, safe, and wireless experience when patients try spinal cord stimulation for the treatment of chronic pain prior to permanent implantation.
"We've developed our new patient-centric Invisible Trial System as a response to physician and patient feedback," said Eric S. Fain, M.D., group president of St. Jude Medical.
Spinal cord stimulation (also known as neurostimulation or SCS) therapy is a proven therapy for managing chronic pain. SCS uses a small implanted medical device and thin wires or leads with electrodes, placed in the epidural space near the spine, to deliver low levels of electrical energy to nerve fibers. These electrical pulses mask or interrupt pain signals as they travel to the brain, reducing pain sensation.
The device delivers traditional tonic as well as burst stimulation to cover a wide array of patients that could benefit from spinal cord stimulation. The accompanying software provides visualization of the leads and their positioning, as well as the contact that they make with the body.
"The system was designed to improve the comfort and usability of our system for patients evaluating spinal cord stimulation therapy to alleviate their chronic pain without focusing on potential barriers such as programming trial cables and systems with complex trial controls."